Syndax Pharmaceuticals, Inc. (SNDX)
19.47
+0.18
(+0.93%)
USD |
NASDAQ |
Sep 01, 10:09
Syndax Pharmaceuticals Cash from Operations (TTM) : -220.64M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -220.64M |
| March 31, 2026 | -278.16M |
| December 31, 2025 | -322.98M |
| September 30, 2025 | -310.88M |
| June 30, 2025 | -302.67M |
| March 31, 2025 | -286.52M |
| December 31, 2024 | -274.90M |
| September 30, 2024 | -258.86M |
| June 30, 2024 | -241.20M |
| March 31, 2024 | -204.92M |
| December 31, 2023 | -160.60M |
| September 30, 2023 | -142.15M |
| June 30, 2023 | -126.04M |
| March 31, 2023 | -130.97M |
| December 31, 2022 | -133.68M |
| September 30, 2022 | -10.07M |
| June 30, 2022 | -6.472M |
| March 31, 2022 | 9.789M |
| December 31, 2021 | 29.13M |
| September 30, 2021 | -87.21M |
| June 30, 2021 | -80.56M |
| March 31, 2021 | -77.92M |
| December 31, 2020 | -71.26M |
| September 30, 2020 | -68.36M |
| Date | Value |
|---|---|
| June 30, 2020 | -58.59M |
| March 31, 2020 | -49.71M |
| December 31, 2019 | -50.61M |
| September 30, 2019 | -52.93M |
| June 30, 2019 | -62.87M |
| March 31, 2019 | -65.49M |
| December 31, 2018 | -68.53M |
| September 30, 2018 | -66.21M |
| June 30, 2018 | -57.92M |
| March 31, 2018 | -54.57M |
| December 31, 2017 | -47.37M |
| September 30, 2017 | -45.06M |
| June 30, 2017 | -46.33M |
| March 31, 2017 | -41.42M |
| December 31, 2016 | -35.16M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | -13.67M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Viking Therapeutics, Inc. | -418.44M |
| Kura Oncology, Inc. | -111.76M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |